### ü´† Cardiomyopathy: Infiltrative Cardiomyopathy on ECG

#### ‚úÖ True Statements
1. **Infiltrative cardiomyopathies**, such as **cardiac amyloidosis**, can present with **low voltage** on electrocardiogram (ECG) despite increased left ventricular wall thickness on imaging.
2. **Low voltage** on ECG is defined as a **QRS amplitude less than 5 mm in the limb leads** or **less than 10 mm in the precordial leads**.
3. The presence of **low ECG voltage** along with **increased wall thickness** on echocardiogram should raise suspicion for **infiltrative cardiomyopathy**, particularly **cardiac amyloidosis**.
4. **Cardiac magnetic resonance (CMR) imaging** is an appropriate diagnostic modality to evaluate for **cardiac amyloidosis**.
5. **Serum protein electrophoresis**, **urine protein electrophoresis**, and **free light-chain analysis** can help diagnose **immunoglobulin light-chain (AL) amyloidosis**.
6. **99m-Technetium pyrophosphate (99mTc-PYP) scintigraphy** of the heart is used to identify **transthyretin (ATTR) cardiac amyloidosis**, which results from **misfolded transthyretin proteins**.

#### üí¨ Extra
1. The provided ECG image shows **markedly low QRS voltage** across limb leads, which is discordant with echocardiographic evidence of left ventricular hypertrophy‚Äîa classic finding in cardiac amyloidosis.
    <figure>
      <img src="Infiltrative cardiomyopathy.jpg" alt="ECG with low voltage QRS in infiltrative cardiomyopathy">
      <figcaption>Electrocardiogram demonstrating low QRS voltage in limb leads, a hallmark of infiltrative cardiomyopathy such as cardiac amyloidosis.</figcaption>
    </figure>
3. **Increased wall thickness** with **low voltage** is an important clue distinguishing infiltrative diseases from hypertrophic or hypertensive cardiomyopathies.
4. **CMR imaging** can detect amyloid infiltration via late gadolinium enhancement and T1 mapping techniques.
6. **ATTR cardiac amyloidosis** can be differentiated from AL amyloidosis noninvasively using a combination of **99mTc-PYP scan** and **monoclonal protein testing**.

---

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Myocardial Disease, Cardiac Amyloidosis

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **Cardiac amyloidosis** results from **deposition of misfolded proteins** within the myocardium, leading to **restrictive physiology** and **heart failure**.
2. **Cardiac amyloidosis** often presents with **normal left ventricular systolic function and cavity size**, but with **abnormal diastolic function**.
3. The two major types of **cardiac amyloidosis** are **immunoglobulin light-chain (AL) amyloidosis** and **transthyretin (ATTR) amyloidosis**.
4. **CMR imaging** is highly sensitive and specific for **cardiac amyloidosis** but does **not distinguish between AL and ATTR types**.
5. In the absence of **monoclonal light chains**, a **positive 99m-technetium pyrophosphate scintigraphy** scan is diagnostic of **ATTR amyloidosis**.
6. **AL amyloidosis** is a **multiorgan disease** associated with **plasma cell dyscrasias** and is diagnosed by biopsy and abnormal light chains.
7. **Endomyocardial biopsy** is not required if **extracardiac biopsy** and **CMR abnormalities** confirm cardiac involvement in **AL amyloidosis**.
8. **TTR gene sequencing** should be performed in patients with suspected **ATTR amyloidosis** to differentiate **hereditary (h-ATTR)** from **wild-type (wt-ATTR)** forms.
9. **Hereditary ATTR amyloidosis (h-ATTR)** is **autosomal dominant** and most commonly caused by a **Val122Ile variant**.
10. **Wild-type ATTR amyloidosis (wt-ATTR)** is an **age-related disorder** and accounts for up to **10‚Äì15% of heart failure cases in older adults**.
11. **Tafamidis** is an **FDA-approved therapy** for **ATTR cardiomyopathy**, shown to **reduce mortality and cardiovascular hospitalization**.
12. **Patisiran** and **inotersen**, which reduce **hepatic transthyretin production**, are approved for **ATTR polyneuropathy** and may benefit **ATTR cardiomyopathy**.
13. **Liver or combined heart-liver transplantation** may be considered in select patients with **hereditary ATTR amyloidosis**.

#### üí¨ Extra
1. Restrictive physiology results from **amyloid deposition** limiting diastolic filling.
2. Diastolic dysfunction contributes to **congestive symptoms** despite preserved ejection fraction.
4. Subtype differentiation is critical for directing **appropriate treatment and prognosis**.
5. **Dual testing** with monoclonal screen and bone scan enables **nonbiopsy diagnosis** of **ATTR cardiac amyloidosis**.
6. Light-chain amyloidosis requires **hematologic therapy**, not amyloid-targeted therapy alone.
9. The **Val122Ile variant** is particularly prevalent in **Black populations** in the United States.
11. Tafamidis stabilizes the **tetrameric structure** of transthyretin and prevents amyloidogenesis.

#### üî∑ Tags
#Cardiology #AmbulatoryCare #CardiacAmyloidosis #InfiltrativeCardiomyopathy #ECGFindings #LowVoltage #CMR #99mTcPyrophosphate #ATTR #ALAmyloidosis #Tafamidis #Transthyretin #HereditaryAmyloidosis #HeartFailure #HematologyOverlap

#### üìô Reference
MKSAP 19 Cardiovascular Medicine. American College of Physicians.

#### üÜî Question ID
CVVDX24007

#### üïí Last Updated
February 2025

---

#### üñºÔ∏è Supplemental Figures

<!--Subtypes of Cardiac Amyloidosis -->
<table>
  <caption><strong>Subtypes of Cardiac Amyloidosis</strong></caption>
  <thead>
    <tr>
      <th>Subtype</th>
      <th>Demographics</th>
      <th>Clinical Manifestations</th>
      <th>Diagnostic Tests</th>
      <th>Therapy</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>AL</td>
      <td>M ‚âà F, aged 40‚Äì80 y</td>
      <td>Nephrotic syndrome, cardiomyopathy, hepatosplenomegaly, neuropathy, carpal tunnel syndrome, bleeding diathesis, periorbital purpura, macroglossia</td>
      <td>
        Analysis for clonal plasma cell dyscrasias with SPEP, UPEP, serum/urine immunofixation, and serum FLC testing<br>
        Bone marrow biopsy<br>
        CMR imaging with LGE<br>
        Endomyocardial biopsy or other tissue biopsy
      </td>
      <td>
        Treatment of plasma cell dyscrasias<br>
        Cardiac transplantation in selected cases
      </td>
    </tr>
    <tr>
      <td>ATTR</td>
      <td>
        h-ATTR: M &gt;&gt; F, aged 55‚Äì75 y<br>
        wt-ATTR: M &gt;&gt;&gt; F, aged 65‚Äì95 y
      </td>
      <td>Cardiomyopathy, carpal tunnel syndrome, spinal stenosis, neuropathy</td>
      <td>
        CMR imaging with LGE<br>
        99m-Technetium pyrophosphate scintigraphy<br>
        Endomyocardial biopsy (controversial)<br>
        Genetic testing
      </td>
      <td>
        Tafamidis<br>
        Diflunisal (off label)<br>
        Patisiran (neuropathy)<br>
        Inotersen (neuropathy)<br>
        Liver or heart-liver transplantation
      </td>
    </tr>
  </tbody>
</table>
<p><em>
AL = amyloid light chain; ATTR = amyloid transthyretin; CMR = cardiac magnetic resonance; F = females; FLC = free light chain; h-ATTR = hereditary amyloid transthyretin; LGE = late gadolinium enhancement; M = males; SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis; wt-ATTR = wild-type amyloid transthyretin.
</em></p>
<p>
Information from Witteles R. Cardiac amyloidosis. 
<a href="https://www.acc.org/latest-in-cardiology/articles/2016/07/07/14/59/cardiac-amyloidosis" target="_blank">
https://www.acc.org/latest-in-cardiology/articles/2016/07/07/14/59/cardiac-amyloidosis
</a>. Accessed September 4, 2024.
</p>

<!--99m-Technetium Pyrophosphate Scan in Hereditary ATTR Cardiac Amyloidosis -->
<figure>
  <img src="99mtcpyp_attr_amyloidosis.jpg" alt="99m-Technetium Pyrophosphate Scan in Hereditary ATTR Cardiac Amyloidosis">
  <figcaption>
    <strong>99m-Technetium Pyrophosphate Scan in a Patient With Hereditary Transthyretin Cardiac Amyloidosis</strong><br>
    Cardiac uptake of the radiotracer is denser than bone uptake at both 1 hour (top panel) and 3 hours (bottom panel).
  </figcaption>
</figure>
